CC Community News Digest (May 25-31)
Assorted news from the last week: FDA issues its final guidance on the RACE Act and specifies when sponsors must conduct pediatric studies for new cancer drugs as well as when those requirements can be waived or deferred. CAC2 Supporting Organization Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers, went public and announced the pricing of its initial public offering of 10,000,000 shares of its common stock. Findings from an analysis of patients’ cognitive functioning after treatment of specific extracranial solid tumors [...] Read more